Immunocytokine

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model

...ch (AACR) demonstrates the vaccine-like ability of immunocytokine proteins combining its anti-phosphatidylserine (an...e the T-cell activating effects of the IL-2 in the immunocytokine to mount a robust and sustained immune response to...tatic strain of breast cancer cells coated with an immunocytokine comprised of the bavituximab equivalent 2aG4 fused...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

...nerated a robust anti-tumor response without any observable toxicity. These immunocytokine fusion proteins incorporating antibodies that target the blood vessels of t...nti-phospholipid antibody similar to Peregrine's bavituximab. The resulting immunocytokine fusion proteins were capable of selectively targeting tumor blood vessels a...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

... VEGF inhibitors; provided validating data for its immunocytokine fusion proteins developed using the company's prop...i-PS antibodies as the targeting agent for immunocytokine fusion proteins based on Peregrine's VTA platform....ed the anti-cancer properties of VTA-based immunocytokine fusion proteins. These are combinations of...

Immunocytokine in Biological Technology

New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform

- Immunocytokine Combining Peregrine's Anti-PS Antibodies and IL-2 Protected 80% of Animals From a Lethal Challenge With a Highly Aggressive Form of Breast Cancer - - New Data Presented at International Conference on Vascular Targeted Therapies in Oncology ...

Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting

...Abstract #2341, New Targets 1: Mechanisms Session) - Poster session scheduled for Monday, April 14, 2008 from 8:00 am to 12:00 pm. -- "An immunocytokine that binds to phosphatidylserine generates an effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor Vaccines Session) - Poster ...